Galaxy Surfactants (NSE: GALAXYSURF) Q3 FY26 results signal portfolio resilience as specialty growth offsets global surfactant pressures
Natural Capsules (NSE: NATCAPSUQ) Q3 FY26 results signal operational recovery after regulatory shock, but fermentation execution risk still looms
Read More 6 minute read Pharma Industry News Vaxxas’ TGA licence unlocks GMP production for HD-MAP vaccines: What this means for clinical trials and global delivery strategy Vaxxas Pty Ltd wins TGA manufacturing licence for needle‑free HD‑MAP vaccines, enhancing clinical scale and delivery potential. Find out what this means next. bySrinathDecember 15, 2025